

To view this email as a web page, go [here](#).

[View in your browser](#)



**INNOVATION AND COMMERCIALIZATION**

---

July 10, 2024

## OHSU Innovates



### LEADERSHIP MESSAGE

We'll keep the leadership message short because this month's newsletter is packed with recent award announcements, new funding opportunities and recognition of outstanding OHSU innovators and their supporters. We'll be back in September with more innovation news and events. Until then, have a great summer!

**Travis Cook, M.S., M.B.A, CLP**  
Senior Director, Technology Transfer

**Aditi Martin, Ph.D.**  
Senior Director, Collaborations and Entrepreneurship

---

## SPONSOR SPOTLIGHT

### **Addressing the gender gap in inventorship**



**Kate Mead, J.D., Partner, Lee & Hayes**

Less than a third of the global science, technology, engineering, and math (STEM) workforce is women. As bad as that seems, the gender gap in inventorship is even more pronounced: only 10.8% of inventors on issued US patents are women. Women, and inventions by women, are being excluded from the patenting process. Because companies usually demand patent exclusivity before developing commercial products and services, this inventorship gender gap suggests that a disproportionate number of technologies developed by women are never commercialized.

Improving methods for determining inventorship may address this problem. Although inventorship is a legal question, inventorship is often effectively determined by individuals without legal training: the innovators who fill out the invention disclosure forms (IDFs) used to track

new inventions.

By focusing on the early stages of invention disclosure, innovators/researchers, technology transfer offices, and other stakeholders can work to diminish the gender gap. First, stakeholders can ensure that any women inadvertently omitted from IDFs submitted by their collaborators are identified early in the invention disclosure process. Stakeholders must actively interview inventors about potential collaborators, and question initial inventorship lists when necessary, to identify all potential inventors who may have been omitted.

Second, stakeholders can encourage more women to prepare and submit their own IDFs. Media campaigns promoting patenting programs, as well as incentives programs (e.g., awards, factors in hiring and promotion decisions, etc.), can encourage more women to recognize benefits of IDF submission and inventorship. Moreover, because women generally have less time to work on optional activities outside of work hours, implementing programs that enable scientists and engineers to draft IDFs, and perform other activities supporting the patenting process, during their workdays may have an outsized impact on women.

---

## NEWS

### **OHSU members advance innovative healthcare solutions with recent funding awards**

#### **2024 Biomedical Innovation Program Drug Discovery Track**

- Congratulations to the research teams led by [Rebecca Spain, M.D., M.S.P.H.](#), [Dan Streblov, Ph.D.](#), and [Sanjay Malhotra, Ph.D.](#), who are this year's recipients of the Biomedical Innovation Programs Drug Discovery Track awards. Read more about the program and the research projects in the [OHSU Now post](#).


#### **Precision Medicine Innovation Co-Laboratory (PMedIC) Innovation Grant**

- Congratulations to Dan Streblov, Ph.D., who also received this year's Innovation Grant from PMedIC. This grant supports collaborative pilot projects annually between OHSU and Pacific Northwest National Laboratory, or PNNL, researchers. Read more about the award and research project in the [OHSU Now post](#).

## **OHSU's 'creatorship' model enables more contributors to reap royalty benefits**

OHSU Tech Transfer has a unique model of royalty sharing, which allows for "creators" to share in royalty even if they do not qualify as an inventor under U.S. patent law. The advantages and benefits of the OHSU creatorship model were recently discussed in the [June issue of Technology Transfer Tactics](#).

## **OHSU-developed vaccine shows promise for cancer prevention**



Researchers at the OHSU Vaccine and Gene Therapy Institute demonstrated that their cytomegalovirus (CMV) vaccine platform, originally developed for HIV, may have applications to prevent cancer. The CMV platform was licensed to VIR Biotechnology and has been used to develop an HIV vaccine that is currently in Phase 1 clinical trials. Read more about the potential utility of this platform for cancer in the [OHSU News article](#).

## GoCheck Kids enters partnership to build an expanded pediatric health screening platform

OHSU startup [GoCheck Kids](#), founded by [David Huang, M.D., Ph.D.](#), entered a new partnership with hearX in June. The GoCheck Kids smartphone-based device allows clinicians to quickly screen a child for vision impairment. A new partnership with hearX aims to add a pediatric hearing screening solution to the platform, furthering GoCheck's mission to ensure that every child is screened for preventable and potentially disabling conditions. Read more about the partnership in the [press release](#).

## Oregon poised to revolutionize future of health care – one drop at a time

OHSU is collaborating with Hewlett Packard to use microfluidic technologies to better detect and treat cancers. Read more about the partnership in a [recent opinion piece](#) co-authored by [Luiz Bertassoni, D.D.S., Ph.D.](#)

## OHSU researcher focuses on workplace well-being and mental health

**Leslie Hammer**  
Ph.D.

Professor, Oregon Institute of Occupational  
Health Sciences  
Director, Oregon Healthy Workforce Center



Research by [Leslie Hammer, Ph.D.](#), has led to the development of the [Workplace Mental Health Training for Managers](#). This evidence-based training gives supervisors and managers supportive tools to improve

employee well-being and mental health. Read more about the training in the [OHSU Now post](#).

## **Center for Experimental Therapeutics translates lab discoveries to treatments**

Scientists from more than 25 laboratories at OHSU are working in collaboration with the Center for Experimental Therapeutics to translate their findings into new treatments for patients. Read about one such therapeutic being developed by the laboratory of [Sanjay Malhotra, Ph.D.](#), in the [OHSU News article](#).

---

### ANNOUNCEMENTS

## **OHSU student takes home top prize at the statewide Invent Oregon competition**

Two OHSU teams, including Ph.D. candidates Josh Vanderpool and Chloe Le Moing, presented their biomedical innovations at the Invent Oregon Collegiate Challenge Finals at the end of June. Vanderpool and co-founder Ildar Fazulyanov took home the top prize of \$10,000 for their invention EaziStep, a medical device that provides multiple mobility options as a knee scooter and hands-free crutch for foot and ankle injuries. Read more about Invent Oregon and the 2024 Finals in the [press release](#).

## **Join OHSU Innovates in advancing leading-edge science – become a sponsor today!**

OHSU Innovates is seeking sponsors for the next fiscal year to continue to build a thriving ecosystem of innovation and entrepreneurship at OHSU and across the region. Sponsor funds support in-person events and virtual programming that bring our community together and provide entrepreneurial education. We offer multiple tiers of sponsorship,

allowing organizations to choose their level of support and sponsor benefits. Interested parties can find more details on the [sponsorship flyer](#) or contact [innovates@ohsu.edu](mailto:innovates@ohsu.edu) directly.

---

## FUNDING OPPORTUNITIES

### **New funding and pitch opportunities for startups**

- NSF Small Business Innovation Research/Small Business Technology Transfer Fast-Track awards. These awards will provide eligible teams the opportunity to submit one proposal for more than \$2 million up to three years. Find out more about the funding opportunity on the [NSF website](#).
- NIH Small Business Transition Grant for New Entrepreneurs. This funding opportunity aims to support career development and R&D under a new entrepreneur's direction. Learn more about the new award on the [NIH website](#) and in an [informational recorded webinar](#).
- Bend Venture Conference. Bend Venture Conference is the largest angel investor conference in the Pacific Northwest. Applications for startups to present at the conference are open through Aug. 9. Find out how to apply through the [BVC website](#).
- Angel Oregon Life and Bioscience (AOBIO). [Register now](#) to join the second cohort in the annual AOBIO program, which begins Aug. 22. AOBIO offers investment-readiness education, connectivity within the local bioscience community and the opportunity to receive an equity investment from local angel investors.

Each week, OHSU Research Development compiles a list of funding opportunities from internal sources, the government and private foundations. [The list is published every Thursday](#).

---

## FEATURED EVENT

# Oregon Bio Women Connect 2024

Join WIS PDX and Oregon Bio Women in connecting with other women in the bio space to discuss the many faces of leadership in industry and academia. Learn how to seize and thrive in leadership opportunities at various stages in your career.

Learn more and register on the [Oregon Bio Association website](#).

---

**WHEN** **Thursday, July 25**  
5–8 p.m. PDT

---

**WHERE** **Twist Bioscience campus**  
**26600 SW Parkway Ave**  
**Wilsonville, OR 97070**

---

**WHO** Women in the bio space

---

**COST** \$35-75

---

## UPCOMING EVENTS

---

**JULY 11** [OBI Accelerate Happy Hour  
Networking](#)

---

**JULY 18** [Lane Powell's Startups & VC Summer  
Series](#)

---

**JULY 20** [Party in the Pinot](#)

---

**JULY 23** [OBI Virtual Lunch and Learn: Patents  
are Easy- Selling is Hard](#)

---

**JULY 30** [Oregon Bio Trivia Night](#)



---

**SEPT. 12**                    [OBI Startup Spotlight Expo](#)

---

**OCT. 1**                        [OBA Biotech Summit 2024](#)

---

**OCT. 17-18**                [Bend Venture Conference](#)

---

## TECHNOLOGIES

### **Featured technologies available for licensing**

A selection of OHSU-developed technologies available for licensing to industry partners. For more technologies visit the [OHSU Technology Portal](#).

[OHSU 2670](#) – Inhibitors of cancer-mediated bone destruction

[OHSU 3081](#) - Novel single-gene biomarker for acute myeloid leukemia prognosis

[OHSU 2812](#) - Label-free microfluidic device for cancer liquid biopsy

[OHSU 3048](#) - Spatially-resolved transcriptomics with enhanced capture and versatility

### **Newly Licensed or Optioned OHSU Technologies**

Congratulations to the inventors of these technologies, which were recently licensed or optioned to outside partners.

[OHSU 0843](#) - Mutated ABL Kinase Domains and [OHSU 0843-A](#) - BCR-ABL P210 Wild Type Plasmid ([Brian Druker, M.D.](#))

[OHSU 1740](#) - Tinnitus Functional Index

[OHSU 1771](#) - Materials from the BioLibrary

[OHSU 2431](#) - Selective PARP11 inhibitor for the treatment of cancer  
([Michael Cohen, Ph.D.](#))

[OHSU 3191](#)- Workplace Mental Health Support Training for Leaders  
([Leslie Hammer, Ph.D.](#))

OHSU 3279 - Handheld non-mydratic ultrawide-field imaging of the retina  
([J. Peter Campbell, M.D., M.P.H.](#), [David Huang, M.D., Ph.D.](#), [Yifan Jian, Ph.D.](#),  
and [Shuibin Ni](#).)

OHSU 3315 - Taking Charge of My Health Care Toolkit ([Rhonda Eppelsheimer, M.S.W.](#), [Ashley Klein](#), and [Jana Peterson-Besse, Ph.D., M.P.H.](#))

OHSU 3344 - AAV epsilon (AAVe) family ([Hiroyuki Nakai, M.D., Ph.D.](#))

## U.S. Patents Issued

Congratulations to the OHSU inventors of these recently issued U.S. patents.

Patent [Patent 11,974,811](#) - Detecting avascular and signal reduction areas in retinas using neural networks

## Researchers in New Industry Funded Research Projects

Congratulations to the Principal Investigators of new non-clinical industry sponsored research.

Natural History Study ([John Brigande, Ph.D.](#))

Targeting chromosomal instability in cancer ([Monika Davare, Ph.D.](#))

Long term AAV antibody expression ([Jonah Sacha, Ph.D.](#))

---

## SPONSORS

Thank you to our current sponsors for their support of OHSU Innovates!



Questions? Contact us at [innovates@ohsu.edu](mailto:innovates@ohsu.edu)

This bi-monthly publication is created in collaboration with OHSU Technology Transfer, OHSU Collaborations and Entrepreneurship, Oregon Clinical and Translational Research Institute, School of Medicine and the Knight Cancer Institute.

©2024 OHSU

This email was sent by OHSU  
3181 S.W. Sam Jackson Park Rd.  
Portland, OR, 97239, US

This email was sent to: [mkubat@mac.com](mailto:mkubat@mac.com)  
[Unsubscribe](#) | [Manage subscriptions](#) | [Update profile](#)  
[OHSU email terms of service](#) | [OHSU privacy policy](#)